United States Patent Office Patented Aug
Total Page:16
File Type:pdf, Size:1020Kb
3,524,846 United States Patent Office Patented Aug. 18, 1970 2. phosphonate esters under essentially neutral conditions 3,524,846 which is especially useful for sensitive molecules such as PROCESS FOR THE DIDEALKYLATION OF PHOSPHONATE ESTERS lipids, steroids, sugars, and nucleosides. Other objects and John G. Moffatt, Los Altos, and Gordon H. Jones, Palo advantages of the present invention will become apparent Alto, Calif.; said Moffatt assignor to Syntex Corpora as the invention is described hereinafter in detail and tion, Panama, Panama, a corporation of Panama from the appended claims. No Drawing. Filed June 2, 1967, Ser. No. 643,078 The term "lower alkyl,' as used herein, refers to a Int, C. C07f 9/40 straight or branched chain hydrocarbon group containing U.S. C. 260-211.5 22 Claims up to six carbon atoms inclusive and thus includes methyl, O ethyl, isopropyl, n-butyl, and the like. The term “alkoxy,' as used herein, means the group --OR wherein R is ABSTRACT OF THE DISCLOSURE lower alkyl as defined hereinabove. The term "dialkoxy Didealkylation of phosphonate esters is effected by phosphinyl' means the heating them with a soluble bromide or iodide salt in an aprotic dipolar solvent at a temperature in excess of 5 100° C. -P(OR) monumanomam group wherein R is lower alkyl as defined hereinabove. This invention relates to a novel process for the di Included in the term "monovalent cation' are lithium, dealkylation of phosphonate ester compounds. More par sodium, potassium, ammonium, tetramethylammonium, ticularly, this invention relates to a process for the di 20 tetraethylammonium, tetra-n-propylammonium, tetra-n- dealkylation of a dialkyl phosphonate ester by heating butylammonium, and the like. Included in the term "di said dialkyl phosphonate ester with a soluble bromide or valent cation' are calcium, barium, and the like. The soluble iodide salt in an aprotic dipolar solvent at a tem term "homo,” as used herein, means a methylene group perature in excess of 100° C. Due to the essentially neutral between the A group and the dialkoxyphosphinyl group conditions of the process of the present invention, it is 25 in the general formula particularly useful for the didealkylation of lipids, steroids, O Sugars and nucleosides having a dialkoxyphosphinyl A-(CH). (OR) groups. Any dialkyl phosphonate ester of the general Formula i.e. wherein x=1, thus representing phosphonate esters I can be didealkylated by the process of the present in 30 that are isosteric with the corresponding phosphate esters vention as shown in the following sequence: O O A-of-coR). A-(CH), (OR) --> A-CH). PoM, o-3 Included among the aliphatic, alicyclic and aromatic (I) (II) groups which A represents are alkyl (including saturated and unsaturated, straight or branched chain alkyl and cycloalkyl) and aryl (including alkaryl and aralkyl) A-(CH2).P (OEt)2 groups, such as methyl, ethyl, propyl, isopropyl, n-butyl, (III) sec-butyl, amyl, hexyl, heptyl, octyl, allyl, methallyl, wherein: 40 cyclobutyl, cyclopentyl, cyclohexyl, methylcyclohexyl, A is an aliphatic, alicyclic, aromatic or heterocyclic cycloheptyl, cylohexenyl, phenyl, tolyl, Xylyl, benzyl, and group; the like, as well as fused ring structures, such as indanyl, R is lower alky; indenyl, naphthyl, acenapthyl, phenanthryl, and cyclo 45 pentanopolyhydrophenanthryl rings, and the like, all of M is a monovalent cation or a divalent cation; which can either be unsubstituted or substituted with one a has a value of 0 or 1; and or more noninterfering substituents, e.g. hydroxy, groups; y has a value of 1 or 2, said value being 1 when M is a hydroxy derivatives, such as alkoxy, e.g. methoxy and divalent cation and 2 when M is a monovalent cation. acyloxy, e.g. acetoxy groups; nitro groups; amino groups; Heretofore, two alkyl groups could be removed from alkylamino groups, such as methylamino, dimethylamino a dialkyl phosphonate ester only under vigorous condi 50 and diethylamino groups; halogens, e.g. fluorine or chlo tions, e.g. by refluxing under acidic conditions. Such a rine; carbonyl derivatives, such as enol ether; acetal and process was limited to those dialkyl phosphonate esters ketal groups, and the like. which were stable under the strongly acidic conditions of An illustrative but by no means exhaustive listing of the method. In addition, it was also possible to effect the 55 dialkyl aliphatic, alicyclic and aromatic phosphonate removal of a single alkyl group. For example, monodeal esters includes: kylation of the dialkyl esters of steroidal 21a-phosphonic acids was effected by treating them with alcoholic sodium diethyl ethylphosphonate; propylmercaptide or alcoholic sodium ethylmercaptide, dibutyl nonylphosphonate; as described by S. Hirai et al., Tetrahedron, vol. 22, dibutyl ethylphosphonate; 1625-1640 (1966). 60 diethyl methylphosphonate; A primary object of the present invention is to provide diethyl 2-octylphosphonate; a process for the didealkylation of dialkyl phosphonate dibutyl phenylphosphonate; esters wherein the removal of two alkyl groups is ac dibutyl n-amylphosphonate; complished in one step under essentially neutral conditions diethyl trichloromethylphosphonate; and whereby the disadvantages set out above are overcome. 65 dibutyl amylnaphthylphosphonate, Another object of the present invention is to provide a and the like. process for the didealkylation of phosphonate esters The above aliphatic, alicyclic and aromatic phospho wherein valuable phosphonic acid salts are obtained nates are converted, by the process of the invention, to the which are useful per se or which can be converted into corresponding intermediary aliphatic, alicyclic and aro the free phosphonic acid. Another object of the present 70 matic phosphonic acid salt (II) and aliphatic, alicyclic invention is to provide a process for the didealkylation of and aromatic phosphonic acid (III), respectively. 3,524,846 3 4. Furthermore, where A in the general formula 36,17a-diacetoxy-21-diethoxyphosphinylmethylpregn O 36,17a-diacetoxy-21-diisopropoxyphosphinylmethyl5-en-20-one; A-(CH), ho R)2 methylpregn-5-en-20-one; given above for a dialkyl phosphonate ester represents 21-diethoxyphosphinylmethyl-36-hydroxypregn-5-en a particular class of substituted aliphatic groups, i.e. a glyceride of saturated and/or unsaturated higher fatty 21-diethoxyphosphinylmethyl-3,3,17a-dihydroxypregn20-one; acids or glyceryl ethers of saturated and/or unsaturated higher aliphatic alcohols, i.e. those having the structure: 36,17a-dihydroxy-21-diisopropoxyphosphinylmethyl5-en-20-one; pregn-5-en-20-one; CH-CH-CHOR 0 17a-acetoxy-21-diethoxyphosphinylmethyl-36-hydroxy &R! pregn-5-en-20-one; herein each of R1 and R2 is a saturated hydrocarbon car 17a-acetoxy-21-diisopropoxyphosphinylmethyl-36-hy boxylic acyl group having a straight-chain and an even droxypregn-5-en-20-one; number of carbon atoms from a value of 8 to a value of 26 inclusive, e.g. caprylyl, capryl, lauryl, myristyl, pal 15 21-diethoxyphosphinylmethylprogresterone; mityl, stearyl, arachidyl, behenyl, lignoceryl, cerotyl, and 21-diethoxyphosphinylprogresterone; the like; an unsaturated hydrocarbon carboxylic acyl 21-diethoxyphosphinylmethyl-17a-hydroxyprogrester group having 18 carbon atoms and unsaturation at the 17a-hydroxy-21-diisopropoxyphosphinylmethylproone; C-9, C-9 and C-12, or C-9, C-12, and C-15 positions, 20 gesterone; e.g. at oleyl, linoleyl, linolenyl, and the like; or a higher 17a-acetoxy-21-diethoxyphosphinylmethylprogresterone; aliphatic group, e.g. hexadecyl, octadecyl, and the like, 17c-acetoxy-21-diisopropoxyphosphinylmethylpro the starting material is a dialkyl lipid phosphonate or a gesterone; dialkyl homolipid phosphonate, i.e. 36-dimethoxyphosphinylcholestan-3ox-ol; O 25 3-dimethoxyphosphinylcholest-2-ene; 36-dimethoxyphosphinylcholest-3-ene; (RO)2P(CH2). CH-CH-CH2OR 36-dimethoxyphosphinylcholestane; R1 3oz-dimethoxyphosphinylcholestane; and will be converted, by the process of the invention, to 3oz-hydroxy-3,6-dimethoxyphosphinyl-5a-androstan-17 the corresponding intermediary lipid phosphonic acid 30 one; and salt (II) or homolipid phosphonic acid salt (II) and lipid 3,3-hydroxy-3oz-dimethoxyphosphinyl-56-pregnan-11,20 phosphonic acid (III) or homolipid phosphonic acid (III), dione, respectively, i.e.: and the like. O The above steroidal starting materials are converted, by 35 the process of the present invention, to the corresponding (HO), P(CH2). CH-CH-CHOR2 intermediary steriod phosphonic acid salt (II) and R1 steriod phosphonic acid (III), respectively. Included among the heterocyclic groups which can be all substituents being as defined hereinabove. Illustrative represented by A are substituted or unsubstituted furfuryl of the lipid phosphate esters represented by this general 40 groups, tetrahydrofurfuryl groups, furanosyl groups, pyra formula, are: nosyl groups, piperidyl groups, pyrrolidyl groups, pyridyl diethyl 2-hexadecyloxy-3-octadecyloxypropylphos groups, thiophene groups, and alkaloid nuclei groupings, phonate; containing, for example, indole, dihydroindole, quinucli diethyl 3,4-dioctadecyloxybutyl-1-phosphonate, 45 dene, and quinoline groups, and the like. Furthermore, and the like. where A in the general formula Furthermore, where A in the general formula O O A-(CH), F (or), A-(CH), coR): 50 given above for the dialkyl phosphonate ester represents given above for a dialkyl phosphonate ester represents a a particular class of substituted or unsubstituted furanosyl particular class of substituted cyclopentanopolyhydro groups, i.e. those having